News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Dynogen Pharmaceuticals, Inc. Files for Bankruptcy
February 25, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Dynogen Pharmaceuticals Inc. filed this week to liquidate under Chapter 7 of the U.S. bankruptcy code — almost a year after a deal to go public fell through.
Twitter
LinkedIn
Facebook
Email
Print
Bankruptcy
MORE ON THIS TOPIC
Mergers & acquisitions
Eli Lilly Enters CAR T Realm With $2.4B Orna Buy, Starting With Autoimmune
February 9, 2026
·
2 min read
·
Dan Samorodnitsky
Layoff Tracker
Delayed Notice Reveals 141 More Layoffs From Genentech in 2025
February 9, 2026
·
52 min read
·
BioSpace Editorial Staff
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
February 3, 2026
·
1 min read
·
Tristan Manalac
